PMID- 36301978
OWN - NLM
STAT- MEDLINE
DCOM- 20221220
LR  - 20221222
IS  - 1098-2299 (Electronic)
IS  - 0272-4391 (Linking)
VI  - 83
IP  - 8
DP  - 2022 Dec
TI  - Circ_0002099 is a novel molecular therapeutic target for bladder cancer.
PG  - 1890-1905
LID - 10.1002/ddr.22005 [doi]
AB  - Bladder cancer (BLCA) acts as one of the most common malignant tumors in the 
      urinary system without ideal therapy. We performed the present study to explore 
      the role and mechanism of Circ_0002099 in BLCA progression. RNase R treatment 
      assay and actinomycin D treatment assay were used to confirm the circular 
      structure of Circ_0002099. Nuclear-cytoplasmic fractionation assay and 
      fluorescence in situ hybridization (FISH) were used to indicate the subcellular 
      localization of Circ_0002099. The CCK-8 assay, colony formation assay, 
      wound-healing assay, Transwell assay, and animal experiment were used to reveal 
      the facilitative effect of Circ_0002099 on BLCA both in vitro and in vivo. 
      Furthermore, bioinformatic analysis, western blot analysis, FISH, and 
      dual-luciferase reporter assay were conducted to demonstrate the role of 
      Circ_0002099 in BLCA progression. The results indicated that Circ_0002099 was 
      significantly upregulated in BLCA and could enhance the progression of BLCA in 
      vivo and in vitro. Furthermore, dual-luciferase reporter assay and FISH assay 
      revealed that Circ_0002099 could regulate miR-217-5p/miR-103a-3p/Kirsten RAS 
      (KRAS) axis in BLCA. In addition, rescue experiments confirmed that 
      miR-217-5p/miR-103a-3p could rescue the facilitative effect of Circ_0002099 on 
      BLCA progression. Moreover, FUS (FUSed in sarcoma) was identified to regulate the 
      Circ_0002099-miR-217-5p/miR-103a-3p/KRAS axis in BLCA progression. The present 
      study suggested that FUS-medicated Circ_0002099 could promote the 
      epithelial-mesenchymal transition process in BLCA progression via 
      miR-217-5p/miR-103a-3p/KRAS axis-WNT/beta-catenin axis. It could be a promising 
      prognostic biomarker and therapeutic target for BLCA.
CI  - (c) 2022 Wiley Periodicals LLC.
FAU - Fang, Ping
AU  - Fang P
AD  - Department of Oncology, The 902nd Hospital of the PLA Joint Logistics Support 
      Force, Bengbu, China.
FAU - Jiang, Qingling
AU  - Jiang Q
AD  - Department of Oncology, The PLA Navy Anqing Hospital, Anqing, China.
FAU - Liu, Sizhong
AU  - Liu S
AD  - Department of Oncology, The 902nd Hospital of the PLA Joint Logistics Support 
      Force, Bengbu, China.
FAU - Gu, Jun
AU  - Gu J
AD  - Department of Oncology, The 902nd Hospital of the PLA Joint Logistics Support 
      Force, Bengbu, China.
FAU - Hu, Kai
AU  - Hu K
AD  - Department of Oncology, Radiotherapy and Chemotherapy, Guangde Traditional 
      Chinese Medicine Hospital, Xuancheng, China.
FAU - Wang, Zishu
AU  - Wang Z
AUID- ORCID: 0000-0002-3641-3734
AD  - Department of Medical Oncology, The First Affiliated Hospital of Bengbu Medical 
      College, Bengbu, China.
LA  - eng
PT  - Journal Article
DEP - 20221027
PL  - United States
TA  - Drug Dev Res
JT  - Drug development research
JID - 8204468
RN  - EC 3.6.5.2 (Proto-Oncogene Proteins p21(ras))
RN  - 0 (MicroRNAs)
SB  - IM
MH  - Animals
MH  - In Situ Hybridization, Fluorescence
MH  - Proto-Oncogene Proteins p21(ras)
MH  - *Urinary Bladder Neoplasms/drug therapy/genetics
MH  - Epithelial-Mesenchymal Transition
MH  - *MicroRNAs/genetics
MH  - Cell Proliferation
MH  - Cell Line, Tumor
OTO - NOTNLM
OT  - KRAS
OT  - bladder cancer
OT  - circRNA
EDAT- 2022/10/28 06:00
MHDA- 2022/12/21 06:00
CRDT- 2022/10/27 13:56
PHST- 2022/09/27 00:00 [revised]
PHST- 2022/07/27 00:00 [received]
PHST- 2022/09/29 00:00 [accepted]
PHST- 2022/10/28 06:00 [pubmed]
PHST- 2022/12/21 06:00 [medline]
PHST- 2022/10/27 13:56 [entrez]
AID - 10.1002/ddr.22005 [doi]
PST - ppublish
SO  - Drug Dev Res. 2022 Dec;83(8):1890-1905. doi: 10.1002/ddr.22005. Epub 2022 Oct 27.